Stocktwits on MSN
A key FDA verdict on this firm’s Alzheimer’s drug is scheduled this week – stock has already gained nearly 15% in a month
Axsome’s supplemental new drug application for AXS-05 was accepted by the FDA last December. ・The drug could be used in about 76% of Alzheimer’s patients who experience agitation, including symptoms ...
Zacks Investment Research on MSN
Analysts estimate Axsome Therapeutics (AXSM) to report a decline in earnings: What to look out for
Axsome Therapeutics (AXSM) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports ...
Several KOLs have highlighted concerns over cost with Symbravo, since fixed-dose combination (FDC) drugs tend to be expensive ...
On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation. The ...
Axsome Therapeutics (NASDAQ: AXSM) has been a red-hot stock to own over the past 12 months. During that stretch, it has soared by around 75%, dwarfing the performance of the S&P 500, which is up by 15 ...
If you are wondering whether Axsome Therapeutics at around US$178 per share still offers value, you are not alone in asking what the current price really reflects. The stock has seen a 4.9% return ...
Shares of Axsome Therapeutics (NASDAQ: AXSM) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, gaining as much as 25% earlier in the day. The move up comes as the S&P ...
Axsome Therapeutics (NASDAQ:AXSM) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ...
On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) reported fourth-quarter 2024 revenues of $118.77 million, up from $71.53 million a year ago, beating the consensus of $117.64 million. Auvelity (oral ...
Axsome Therapeutics is now a self-sustaining CNS drug company with three marketed products and a robust late-stage pipeline. Revenue visibility anchors downside risk; the investment thesis pivots to ...
Axsome Therapeutics (NASDAQ:AXSM) announced Tuesday that solriamfetol, its experimental therapy for attention deficit hyperactivity disorder (ADHD), reached primary and secondary goals in a Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results